New pill takes on hard-to-treat lung cancer in major trial
NCT ID NCT07242274
First seen Nov 21, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests a new pill, JMKX001899, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 472 adults who have already tried at least one other treatment will be randomly assigned to receive either the new drug or chemo. The goal is to see if the targeted therapy works better and has fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.